Intercept Pharma (ICPT) Tops Q2 EPS by 21c; Offers FY22 Revenue Guidance

Intercept Pharma (NASDAQ: ICPT) reported Q2 EPS of ($0.25), $0.21 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $71.76 million versus the consensus estimate of $95.98 million.

GUIDANCE:

Intercept Pharma sees FY2022 revenue of $325-345 million, versus the consensus of $386.2 million.

For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business
• Nvidia and Broadcom earnings: TD Cowen says earnings won’t settle big questions